Cargando…
Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases
BACKGROUND: Pharmaceutical compounding of orphan active ingredients can offer cost-effective treatment to patients when no other drug product is available for a rare disease or during periods of drug product shortages. Additionally, it allows customized therapy for patients with rare diseases. Howev...
Autores principales: | Vanhoorne, V., Peeters, E., Van Tongelen, I., Boussery, K., Wynendaele, E., De Spiegeleer, B., Remon, J. P., Vervaet, C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676613/ https://www.ncbi.nlm.nih.gov/pubmed/31370862 http://dx.doi.org/10.1186/s13023-019-1154-x |
Ejemplares similares
-
Orphan Drugs, Compounded Medication and Pharmaceutical Commons
por: Hendrickx, Kim, et al.
Publicado: (2021) -
Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs
por: Byttebier, Geert, et al.
Publicado: (2021) -
EHMTI-0056. Self-medication of headache: identification of subgroups of patients through cluster analysis
por: Mehuys, E, et al.
Publicado: (2014) -
Reimbursement of orphan drugs in Belgium: what (else) matters?
por: Picavet, Eline, et al.
Publicado: (2014) -
Continuous Twin Screw Granulation: A Review of Recent Progress and Opportunities in Formulation and Equipment Design
por: Portier, Christoph, et al.
Publicado: (2021)